DarshanTalks Podcast

Send us Fan Mail NOT LEGAL ADVICE For decades, cannabis research in the U.S. was stifled by Schedule I restrictions, requiring high-security vaults, mountains of paperwork, and extremely limited supply chains. With Executive Order 14370, the landscape has shifted. Marijuana is moving to Schedule III, and the rules of the game have officially changed.In this episode of KLF Deep Dive, attorney-pharmacist Darshan Kulkarni breaks down the practical impact of this reclassification for clinical trial sponsors. We move beyond the headlines to discuss the "pharmacy-style" compliance now required and the hidden pitfalls of using non-pharmacist staff at trial sites.Key Topics Covered:The Security Shift: Why you can ditch the steel vaults, but why your new "pharmacy" status brings a different set of DEA headaches.Supply Chain Normalization: Moving away from the "one-plant" monopoly toward a traditional pharma infrastructure.The Real-World Evidence (RWE) Invitation: How the FDA is encouraging the use of patient records and "real-world stories" to prove efficacy.The Compliance Trap: Why vetting your trial sites’ staffing—specifically the use of CRNAs vs. Pharmacists—is now a top-tier regulatory risk.Targeting Federal Grants: Why studies focusing on veterans and the elderly are currently "first in line" for federal support.The Bottom Line: The federal government has moved from stopping research to starting it. But as a sponsor, your site list just got bigger—and so did your responsibility to ensure they aren't just pretending to be compliant.Support the show: www.kulkarnilawfirm.comSupport the showwww.kulkarnilawfirm.com

Send us Fan MailIs your career protected from your company’s mistakes? For decades, a Federal Consent Decree was a corporate headache. Today, it’s a personal professional death sentence. In this episode, Darshan Kulkarni breaks down the seismic shift in federal enforcement: why agencies are now naming CEOs, CMOs, and Heads of Clinical operations by name in injunctions. We explore the "Delegation Trap," the rise of the Office of Data Reliability, and the KLF Playbook for ensuring your name never appears on a federal blackball list. Support the showwww.kulkarnilawfirm.com

Send us Fan Mail In this episode of the KLF Deep Dive, Darshan Kulkarni deconstructs a persistent and dangerous myth circulating in life sciences and investment circles: the Private Membership Association (PMA). While often marketed as a "contract-based loophole" to evade FDA oversight and civil liability, the reality in federal court is starkly different. Darshan examines the constitutional limits of "freedom of association" and analyzes key case law—including Little v. Q Lasers—to demonstrate why PMAs are viewed by judges as red flags rather than legal shields. If you are advising clients on regulatory shortcuts, this is a must-listen briefing on maintaining professional integrity and statutory compliance. Support the showwww.kulkarnilawfirm.com

Send us Fan Mail What would happen if your clinical trial sites were suddenly banned from using you? In this episode, Darshan Kulkarni uncovers a hidden regulatory shift: state licensing boards are tightening the "Corporate Practice of Medicine" and "Fee Splitting" laws. If your recruitment fees are tied to enrollment or revenue, you aren't just a vendor—you’re a legal liability. We break down the MSO structures that are failing, the "Red Zones" in state law, and how KLF re-architects your contracts to make you the safest, most scalable partner in the life sciences industry. Support the showwww.kulkarnilawfirm.com

Send us Fan Mail In this tactical masterclass, Darshan Kulkarni breaks down the critical legal architecture required to protect clinical trial sites during rapid expansion. As PIs and Sub-Investigators move between organizations, the risk of losing proprietary data and patient continuity skyrockets. Learn the specific clauses—from non-solicitation to transition requirements—that ensure your site retains its value and your sponsors remain confident. Don't let your most valuable assets walk out the door; learn how to lock down your contracts today. Support the showwww.kulkarnilawfirm.com

Send us Fan Mail In this episode, Darshan Kulkarni breaks down the staggering legal difference between the branded drugs you know (like Mounjaro) and the compounded versions flooding the market. Using a brilliant "Coke vs. RC Cola" analogy, we explore why "clean vats" aren't the same as "proven science." If you are a patient, a provider, or a legal professional in the life sciences space, you need to understand the four pillars of FDA approval—and why some of the most popular drugs on the market today are legally allowed to skip the hardest parts Support the showwww.kulkarnilawfirm.com

Send us Fan MailStop playing compliance theater. In this episode, Darshan Kulkarni pulls back the curtain on a dangerous trend in the life sciences: the over-reliance on contract sales forces without the legal control to back them up. Many companies believe they’ve "solved" the incentive pay problem, only to realize the OIG hasn't changed its mind since 1998.We break down why the "Pikachu face" won't save you when the government comes knocking, the myth of the "basically an employee" legal status, and why your business model might be a walking Anti-Kickback violation. If you’re paying for results but can’t control the behavior, you aren’t scaling—you’re gambling.Support the showwww.kulkarnilawfirm.com

Send us Fan Mail Is AI the savior of clinical research costs, or a ticking time bomb for data integrity? In this episode, Darshan Kulkarni dives into the murky waters of AI-driven sponsor protocols. We explore how AI is being used to mask—and unmask—data falsification, and what life science sponsors must do to ensure compliance before the regulators knock. If you’re using AI to "make life easier," you might be making your legal defense much harder. Support the showwww.kulkarnilawfirm.com

Send us Fan Mail"The model said so" is not a defense. In the rush to integrate AI into drug discovery, life science companies are sprinting toward a compliance cliff. In this episode, Darshan Kulkarni—pharmacist and FDA regulatory lawyer—strips away the marketing hype to reveal the "messy reality" of AI in regulated environments.We dive deep into the three pillars of risk that can sink a biotech firm:Data Integrity: Why AI scales bad data faster than you can fix it.The Ownership Crisis: Why current collaboration agreements aren't ready for probabilistic inventorship.The Accountability Gap: Who does the DOJ point to when the algorithm makes a $500M mistake?If you are an executive or general counsel in the life sciences, this is the briefing you need to hear before your next M&A due diligence or patent filing.Support the showwww.kulkarnilawfirm.com

Send us Fan MailIn this episode of DarshanTalks, host and attorney-pharmacist Darshan Kulkarni explores the unsettling transition from "Googling your symptoms" to "Chatting with your symptoms." It’s 10:47 PM—you have chest tightness and a chatbot is your only companion. But is the algorithm reassuring you, or is it gaslighting a medical emergency?We go beyond the hype to examine the February 9, 2026, Nature Medicine study (as reported in the New York Times) which reveals a staggering gap between AI’s medical exam scores and its real-world ability to triage human beings. Darshan breaks down the "Black Box" of emergency room triage, the evolution of FDA Software as a Medical Device (SaMD) regulations, and why your zip code might determine if your data is protected under new 2026 state privacy laws in Washington, California, and Maryland.Key topics include:The "Midnight Triage" Trap: Why AI struggles with the nuance of human shame, fear, and "atypical presentations" in the ER.FDA & the "Glass Box": Navigating the new 2026 guidance on Clinical Decision Support (CDS) software and the legal line between "wellness devices" and "medical devices."Liability & Malpractice: Why an algorithm can’t carry insurance—and what that means for the doctors who follow (or ignore) AI alerts.The Data Privacy Patchwork: How HIPAA fails you once you leave the hospital portal and enter the world of consumer AI chatbots.Healthcare is a human endeavor, and accountability requires a human name. Learn how to use AI as a starting point without letting it be your final conclusion.Support the showwww.kulkarnilawfirm.com

Send us Fan Mail On January 27, 2026, the HHS Office of Inspector General (OIG) changed the game for pharmaceutical manufacturers. In a landmark Special Advisory Bulletin, the government officially opened a "green lane" for direct-to-patient (DTP) drug sales, specifically addressing the rise of cash-pay programs like TrumpRx. In this episode, we break down why the OIG is now prioritizing lower costs over traditional Anti-Kickback Statute (AKS) risks for cash-paying patients—including those on Medicare and Medicaid. If you are a life sciences executive or legal counsel, this is the compliance roadmap you’ve been waiting for. Support the showwww.kulkarnilawfirm.com

Send us Fan MailThe DOJ just changed the rules of the game for the Life Sciences industry. As of January 2025, transferring "Bulk Sensitive Personal Data" to countries of concern—specifically China—is no longer just a compliance hurdle; it’s a potential federal violation. In this episode, Darshan Kulkarni breaks down the six categories of data you must protect immediately, from genomic data to precise geolocation. If you are handling safety data across borders, this is your mandatory executive briefing. Support the showwww.kulkarnilawfirm.com

Send us Fan MailIs your state "sandbox" a playground or a legal minefield? In this episode, Darshan Kulkarni—pharmacist and attorney—dissects the quiet movement of states like Utah allowing AI to manage and renew prescriptions. While the innovation is exciting, the federal government is watching closely.We break down the three massive risks facing life science companies and healthcare providers today:Clinical Logic Failures: Why a state sandbox can't fix bad AI medicine.The Liability Void: If the AI misses a symptom, who stands in court?The Supremacy Clause: Why state "waivers" don't protect you from the FDA.If you are navigating the intersection of health-tech and regulation, this is the practical take you need to stay compliant and protected.Support the showwww.kulkarnilawfirm.com

Send us Fan Mail The OIG has officially shifted the goalposts for Direct-to-Consumer (DTC) and Direct-to-Patient (DTP) programs. For years, federal healthcare discounts were a "no-go zone," but a new dual-track strategy is emerging—if you know how to build the firewall. In this episode, Darshan Kulkarni breaks down the three core regulatory pillars required to bypass PBM middlemen without triggering federal anti-kickback statutes. We discuss the "one-year commitment" rule, the "seeding" trap, and why your current marketing strategy might be an unintentional red flag for regulators. If you are in Life Sciences commercialization, the "wait and see" approach is now your biggest liability. Support the showwww.kulkarnilawfirm.com

Send us Fan Mail In this episode of KLF Deep Dive, Darshan Kulkarni uncovers the catastrophic risks clinical trial sites face when they fail to vet their staff against federal exclusion lists. We move beyond simple compliance to discuss the "off-the-books" penalties that can end a career or a company. If you’re in the life sciences, this is the legal shield you can't afford to ignore. Support the showwww.kulkarnilawfirm.com

Send us Fan MailUndeclared allergens remain the #1 cause of food recalls in the U.S., yet many brands still treat labeling as a "marketing" task rather than a "legal" one. In this episode of KLF Deep Dive, Darshan Kulkarni breaks down the regulatory horror stories of major brands—from Nugo to Frito-Lay—and explains why the FDA doesn't care if your co-manufacturer messed up. If your name is on the bag, you own the risk.Learn how to transition from "marketing font arguments" to FSMA-compliant allergen controls that survive federal scrutiny.Support the showwww.kulkarnilawfirm.com

Send us Fan Mail Think HIPAA is your biggest hurdle in pharma marketing? Think again. In this episode of KLF Deep Dive, Darshan Kulkarni reveals why focusing solely on HIPAA leaves a massive, unregulated gap in your compliance strategy. We break down the "layered system" of risk—from aggressive state privacy laws and medical privacy statutes to the DOJ’s massive 2025 Bulk Data Rule. Whether you’re running patient engagement campaigns or leveraging marketing automation, you’ll learn why the tools you use to scale might be the very tools that trigger a regulatory audit. Don't leave your firm's reputation to a "narrow slice" of engagement. Support the showwww.kulkarnilawfirm.com

Send us Fan Mail The "handshake" era of cosmetic compliance is officially over. Under new authorities in Sections 605, 610, and 704, the FDA has moved from simple observation to an aggressive "access and copy" mandate. In this episode, Darshan Kulkarni breaks down the "SAHCOD" threat and explains why your internal communications, medical assessments, and even cross-contamination logs are now fair game for federal investigators. If you handle raw materials or shared manufacturing equipment, your entire catalog could be at risk of a forensic audit. Learn where the FDA's power ends—and where your defense begins. Support the showwww.kulkarnilawfirm.com

Send us Fan Mail In clinical research, if it isn't documented, it never happened. Many site owners mistake a competent team for a compliant one—a mistake that leads to disastrous FDA inspections and lost sponsor contracts. In this KLF Deep Dive, Darshan Kulkarni reveals the specific training SOPs, log templates, and contract clauses required to protect your site. Learn how to bridge the gap between "doing the work" and "proving the work" so you can demonstrate a culture of readiness that sponsors trust. Support the showwww.kulkarnilawfirm.com

Send us Fan MailIs your marketing team building a brand or a federal case? In this episode, we deconstruct the $1.2 billion collapse of Boom Care. What looked like a runaway success story in the wound care space was actually a systematic violation of the False Claims Act. We break down the three fatal mistakes that led to 15-year prison sentences for executives: prioritizing reimbursement over medical necessity, incentivizing volume over value, and treating compliance as an afterthought. If you are an executive in biopharma or med-tech, this is a mandatory masterclass in where "aggressive growth" ends and criminal exposure begins. Support the showwww.kulkarnilawfirm.com

Send us Fan MailIn January 2026, the FDA sharpened the line between helpful software and regulated medical devices. If your AI sits inside an EHR, providing "black box" recommendations that a clinician can’t independently verify in seconds, you aren't just drifting into a regulatory gray area, you’re likely standing outside the "safe zone."In this episode, we break down the high-stakes intersection of FDA transparency, OIG inducement analysis, and the reality of clinical workflows.In this episode, we cover:The 2026 FDA Update: Why "independence" is the new metric for non-device CDS.The Transparency Test: If a physician has to call your engineering team to explain a recommendation, you've already lost.OIG & The Anti-Kickback Statute: How "nudging" prescribing behavior creates massive financial liability, regardless of what you call your software.Automation Bias: How "fast and confident" AI leads to clinician reliance that regulators now view as a red flag.The FTC Factor: Why vague disclosures and hidden logic are no longer defensible under consumer protection standards.Key Takeaway:Regulators don't care if the tech works; they care if the compliance story holds up. If you cannot prove your recommendations are separated from commercial influence and fully explainable, you are exposed.Are you ready to defend your AI? Don't wait for an investigator to walk through your door.Subscribe to the KLF Deep Dive Podcast & Newsletter to navigate these risks before they turn into enforcement problems.Support the showwww.kulkarnilawfirm.com

Send us Fan MailIn this episode, Darshan Kulkarni exposes a massive legal shift that is quietly dismantling the "Practice of Medicine" defense. We track the whiplash from the 2021 Ivermectin court victories to the DOJ’s aggressive 2025 memorandum targeting gender-affirming care.Is "Intended Use" being weaponized as a high-tech surveillance tool? If the government can criminalize the intent behind a legal hormone, what does that mean for every manufacturer and physician operating in the off-label space? Darshan breaks down the April 2025 DOJ Memo and why your compliance strategy is likely outdated. This isn't just a policy change; it’s a precedent that puts every drug in the market at risk.Support the showwww.kulkarnilawfirm.com

Send us Fan Mail In this episode of the KLF Deep Dive, Darshan Kulkarni sits down with Phyllis Marcus, Vice President of the National Advertising Division (NAD) and former FTC veteran. They unpack the complex "grey area" where healthcare professional (HCP) communications bleed into the public consumer space. Phyllis reveals why labeling an ad "For Healthcare Professionals Only" may no longer protect a company from regulatory scrutiny and explains the NAD’s role as an independent adjudicator in high-stakes pharmaceutical disputes. If you are navigating the intersection of FDA, FTC, and NAD jurisdictions, this masterclass in advertising law is essential listening. Support the showwww.kulkarnilawfirm.com

Send us Fan MailState governments are racing to innovate by allowing AI to renew and improve prescriptions—but are they walking into a federal trap? In this episode of KLF Deep Dive, Darshan Kulkarni breaks down the "Utah Sandbox" model and the three massive warning signs flashing for the life sciences industry. From misdiagnosis risks to the nightmare of liability ownership, we explore why "innovation" doesn't grant immunity from federal law or malpractice lawsuits. If you are a healthcare executive or legal professional, this is the regulatory reality check you can't afford to miss. Support the showwww.kulkarnilawfirm.com

Send us Fan MailIn the high-stakes world of Life Science M&A, hiring expert consultants for GXP, IT, and data privacy is standard operating procedure. But there is a hidden structural flaw in most due diligence programs: Scope Creep. When a consultant identifies "high risk" in a data transfer mechanism, they aren't just giving a business metric—they are venturing into legal opinion. Without the protection of attorney-client privilege, these "compliance scorecards" and "heat maps" are discoverable goldmines for post-acquisition lawsuits and regulatory actions.In this episode of KLF Deep Dive, we break down why all diligence must be commissioned and controlled through legal counsel. Learn how to transform operational findings into binding indemnities and ensure your next acquisition doesn't become your next legal nightmare.Support the showwww.kulkarnilawfirm.com

Send us Fan Mail The NIH just dropped a regulatory bombshell: Notice NOT-OD-26-032. Effectively immediately, Basic Experimental Studies in Humans (BESH) are no longer classified as "Clinical Trials" for reporting purposes. Is this a victory for common sense, or an administrative "fudge" to hide years of academic non-compliance? In this episode, Darshan Kulkarni breaks down why this "Great Reset" changes the mathematics of due diligence, tech transfer, and company valuations. If you are licensing university tech, your "human clinical data" might have just been downgraded to "well-funded experiment." Support the showwww.kulkarnilawfirm.com

Send us Fan MailSupport the showwww.kulkarnilawfirm.com

Send us Fan MailIn this episode of KLF Deep Dive, we examine a chilling shift in regulatory enforcement: the weaponization of "Intended Use." If the science hasn't changed and the law hasn't changed, why is the FDA pivoting from "advice-giving" to "subpoena-swinging"?Host Darshan Kulkarni breaks down the legal whiplash between the Ivermectin era and the current crackdown on gender-affirming care. We explore why the "Practice of Medicine" shield is disappearing and what this "Rule of the Mood" means for pharmaceutical executives trying to navigate an increasingly political landscape. This is about the survival of the rule of law in life sciences.Support the showwww.kulkarnilawfirm.com

Send us Fan MailIn this episode, Darshan Kulkarni dives into the terrifying reality of compliance failures at clinical trial sites. While most directors worry about standard fines, the true danger lies in the "off-the-book" penalties and the looming threat of criminal prosecution for employing excluded physicians. If you aren't auditing your lists correctly, you aren't just risking a citation—you're risking your entire career. Support the showwww.kulkarnilawfirm.com

Send us Fan MailFor decades, a "clean mental line" existed: Doctors prescribe, and companies don't promote off-label. That line just got a lot messier. In this episode, Darshan Kulkarni breaks down the Hsaio Declaration—a seismic shift in DOJ enforcement that aims to turn independent medical judgment into evidence of a federal crime.We dive into the University of Pittsburgh Medical Center (UPMC) subpoena battle, the fallout of Executive Order 14187, and why "Scientific Exchange" may no longer be a safe harbor for Medical Affairs. If you are a physician, a compliance officer, or a pharma marketer, the blast radius of this new theory is larger than you think. Is your prescribing pattern being "engineered" by marketing? The DOJ thinks so.Support the showwww.kulkarnilawfirm.com

Send us Fan MailIn this episode, we sit down with world-renowned futurist Bruce McCabe to cut through the hype of large language models like ChatGPT and explore the "stunningly optimistic" reality of Specialist (Narrow) AI.Bruce shares insights from his global travels to research labs, explaining why the future of medicine isn’t one "God-like" AI, but rather a "hive mind" of tens of thousands of highly trained, testable, and trustworthy specialist systems. From early tumor detection in radiology to the revolutionary protein-folding predictions of AlphaFold, we discuss how AI is incrementally building toward a more precise and efficient healthcare system.Key Discussion Points:Moving Beyond the Hype: Why the current "AI correction" is only about large language models, and why narrow AI is actually underhyped.The Power of Specialist Systems: How AI trained on specific datasets (like 100,000 X-rays) achieves higher reliability and lower false-positive rates than general models.The "Hive Mind" Concept: A future where thousands of specialist AIs interact to provide comprehensive patient care while maintaining data anonymity.Trust and Testing: How we measure the trustworthiness of AI in dermatology and diagnostics through historical clinical data.Edge Computing & Privacy: Solving the patient privacy dilemma by using Small Language Models (SLMs) that live on local hospital servers rather than the cloud.The Next Frontier: The role of AI in material science, drug construction, and programmable medicines like CAR T-cell therapy.About Our Guest:Bruce McCabe is a futurist, speaker, and author who spends half the year visiting scientists and innovators around the world to understand how technology will shape our future. You can find his research and book him for speaking engagements at BruceMcCabe.com.Support the showwww.kulkarnilawfirm.com

Send us Fan MailIn this episode of DarshanTalks, host and attorney-pharmacist Darshan Kulkarni deconstructs the legal "scorched-earth" offensive currently reshaping the weight loss drug industry. Following the February 2026 announcement that the GLP-1 shortage is officially resolved, the "Golden Age" for compounders has vanished overnight, leaving companies like Hims & Hers in the crosshairs of both the FDA and Novo Nordisk.Darshan takes us from the tragic "ghost" of the 2012 NECC fungal meningitis outbreak to the modern-day "Compounding Wild West." We explore the crucial differences between Section 503A and 503B pharmacies and why adding Vitamin B12 to a patented molecule isn't the "customization" compounders claim it is.Key topics include:The NECC Legacy: How a 2012 tragedy created the Drug Quality and Security Act (DQSA) and why the FDA is using it to end the mass-marketing of copycat drugs.The Science of the "Bluff": Why "not adulterated" does not mean "safe and effective" under the FD&C Act.Novo Nordisk vs. Hims & Hers: The billion-dollar patent battle and why the DOJ is now getting involved.The Shortage Shield: What happens to telehealth platforms the moment the FDA "Shortage" flag disappears.Don't let your healthcare be decided by an Instagram ad. Understand the intersection of biochemistry and federal law to protect your health and your practice.Support the showwww.kulkarnilawfirm.com

Send us Fan MailIn this episode, I sit down with FDA compliance attorney Heather Butos to unpack two topics most cosmetic pros ignore until it’s too late: INCI (ingredient) names and MOCRA (the new cosmetic law).We talk about how ingredient naming is not just labeling, it’s a strategic business decision that can make or break product marketing. Heather breaks down how the Personal Care Products Council influences naming conventions, why companies struggle to sell ingredients when they can’t describe them well, and what’s actually allowed under FDA rules.We also dive into the Modernization of Cosmetics Regulation Act (MOCRA). We discuss what’s already in effect, what’s still vague, and why this transition period is both confusing and critical. Along the way we share real-world GMP audit stories, how COVID shaped compliance, and why walking the factory floor gives better regulatory insight than just reading guidance documents.This is not your typical cosmetic compliance talk. If you make or sell cosmetics, personal care products, or ingredients, pay attention.Show Notes (Bulleted)What are INCI names and why they existThe Personal Care Products Council and how INCI naming worksHow ingredient naming crosses into marketing strategyReal-world examples of label creativity and regulatory riskMaking sense of MOCRA — what’s live, what’s stuckWhy registration, adverse event reporting, and safety substantiation matter nowWhat we still don’t know about cosmetic GMP enforcementGMP audits vs desk compliance — why experience mattersU.S. vs EU regulatory contrast (quick take)Tips for staying compliant while FDA rules evolveWhat You’ll LearnHow to think about ingredient names as part of your product strategyWhat’s actually required vs what’s still vague in cosmetic regulationHow the naming process works with industry groupsHow MOCRA changes the compliance landscapeReal compliance lessons from factory auditsResources MentionedPersonal Care Products CouncilMOCRA (Modernization of Cosmetics Regulation Act)Cosmetic registration and listingAdverse event reporting basicsWho This Is ForCosmetic brand owners and foundersIngredient suppliers and formulatorsRegulatory affairs professionalsLegal and compliance teamsAnyone confused by cosmetic labeling rulesRecommended Chapters (Timestamped)Use these in Buzzsprout chapter markers:0:00 — Intro 1:30 — What INCI ingredient names are 3:30 — How ingredient naming affects marketing 7:00 — Creative labeling and regulatory limits 10:00 — GMP audits and manufacturing reality 13:50 — What MOCRA is 16:30 — Which MOCRA rules are live 19:00 — What’s still vague or coming 21:30 — EU vs US differences 24:00 — Tips for compliance 27:00 — OutroSupport the showwww.kulkarnilawfirm.com

Send us Fan MailLife sciences M&A is picking up again, but today’s deals look nothing like they did two years ago.In this episode, Darshan Kulkarni sits down with Stephanie Trunk, Partner at ArentFox Schiff, to unpack what’s really driving renewed deal activity and what buyers are still missing in diligence. From U.S. manufacturing incentives and drug pricing exposure to China risk, DOJ enforcement, compliance culture, and AI, this conversation goes beyond headlines and into deal reality.If you are buying, selling, or advising life sciences companies, this episode is a must-listen.Key Topics DiscussedWhy life sciences M&A slowed down and why it’s backThe shift from mega-deals to asset-specific acquisitionsWhy U.S. manufacturing location now affects deal valueAccelerated approvals and “Buy America” incentivesDrug pricing risks buyers can no longer ignoreASP, inflation rebates, Medicaid rebate cap removal, and 340B pressurePolitical risk in drug pricing and government scrutinyChina partnerships, data transfer rules, and biosecurity concernsDirect-to-patient models and new HIPAA exposureUsing Sunshine Act and other public data in diligenceCompliance programs, culture, and successor liabilityWhy compliance issues still rarely kill dealsThe emerging role of AI in diligence and enforcementThe IP diligence problem no one wants to solveWhy This Episode MattersLife sciences deals are no longer just about science and revenue projections. Manufacturing geography, pricing exposure, compliance culture, data security, and enforcement risk now directly shape valuation and post-close outcomes.Ignoring these issues does not make them go away. It just shifts the risk to the buyer.GuestStephanie Trunk Partner, ArentFox Schiff Life Sciences | CMS | OIG | Reimbursement | Fraud & AbuseStephanie advises pharmaceutical, biotech, and device companies on regulatory risk, government pricing, and transaction diligence.📧 [email protected] 🔗 ArentFox Schiff Life Sciences BlogHostDarshan Kulkarni Founder, Kulkarni Law Firm Host, DarshanTalks📧 [email protected] 🔗 LinkedIn: Darshan KulkarniSubscribe & ConnectIf life sciences compliance, enforcement, or deals matter to your business, subscribe for more conversations like this. Questions or ideas for future episodes? Reach out anytime.Support the showwww.kulkarnilawfirm.com

Send us Fan MailA brief discussion on the various cosmetic ingredients used by cosmetic manufacturers and the concerns FDA has recently found as a result of their own study into the processSupport the showwww.kulkarnilawfirm.com

Send us Fan MailFederal enforcement is changing. Regulators aren’t just going after companies anymore. They’re naming CEOs, CMOs, heads of clinical, quality, and operations in consent decrees and injunctions. Once your name is on that document, it follows you for years and shapes your career.In this episode we unpack:Why enforcement has shifted toward individual accountabilityHow repeated compliance failures trigger personal liabilityData integrity and why it matters more than everWhy clinical research and telehealth are now in regulators’ crosshairsWhat personal obligations look like inside a consent decreeWhat executives should be doing now to protect themselvesIf you lead in an FDA-regulated space, this one matters.Get show notes and resources at www.kulkarnilawfirm.comSubscribe for weekly breakdowns of enforcement trends that actually affect you.Support the showwww.kulkarnilawfirm.com

Send us Fan Mail Everyone’s talking about the new food pyramid like it’s diet advice. I’m here to tell you it’s regulatory policy in disguise. In this episode I break down why this change matters beyond grocery aisles: school meal rules, food labeling, federal purchasing, and how the government quietly reshapes what counts as “healthy.” If you think this is just about fats and grains, think again. This affects prices, marketing claims, and what ends up on kids’ plates. I’m a food and drug lawyer focused on how policy becomes enforcement, and I’ll tell you what you need to know in straight language. Support the showwww.kulkarnilawfirm.com

Send us Fan MailEpisode DescriptionIn this episode, Darshan Kulkarni sits down with former FDA Commissioner Robert Califf for a wide-ranging conversation on FDA authority, politics, guidance, and public trust. From the loss of Chevron deference to the role of FDA as a referee, Dr. Califf explains how regulation really works and why wealth inequality has become the most serious health issue in the United States.Episode SummaryWhat does it really take to run the FDA, and how political should the agency be? Former FDA Commissioner Robert Califf reflects on his path to the role, the skills a commissioner actually needs, and why FDA must act as an impartial referee rather than a political actor. The conversation explores guidance versus regulation, the loss of Chevron deference, industry expertise, the revolving door debate, and how social determinants of health shape outcomes far more than medicine alone. A candid, opinionated look at regulation from someone who has seen every side of it.Key Topics DiscussedHow Dr. Califf became FDA Commissioner twiceWhy FDA should act as a referee, not a combatantGuidance documents and how they really functionPolitics, policy, and product level decision makingPreparing for the loss of Chevron deferenceWealth inequality as the biggest health problem in the U.S.Social determinants of health and FDA’s roleGeneric drugs, tobacco, and public health impactDigital health hype versus real-world impactThe FDA–industry revolving door debateWhy This Episode MattersAs courts, politicians, and industry challenge agency authority, understanding how FDA decision making actually works matters more than ever. This episode explains what regulation can and cannot do, where political pressure becomes dangerous, and why ignoring inequality undermines health outcomes no matter how advanced the science becomes.GuestRobert Califf Former Commissioner, U.S. Food and Drug Administration Instructor in Medicine, Duke UniversityDr. Califf has served twice as FDA Commissioner and brings decades of experience across clinical medicine, academia, industry, and government.HostDarshan Kulkarni Founder, The Kulkarni Law Firm Host, DarshanTalksCall to ActionSubscribe for more conversations on FDA regulation, enforcement, policy, and healthcare compliance. Questions or ideas for future episodes? Call, click, or email.Support the showwww.kulkarnilawfirm.com

Send us Fan MailGLP-1 weight loss programs are everywhere right now, especially in the med spa space. For M&A lawyers and deal teams, that popularity comes with serious regulatory risk.In this episode, Darshan breaks down why GLP-1 compliance has quietly become a dealbreaker in healthcare acquisitions. What used to be framed as an FDA issue is now actively being enforced by state attorneys general using consumer protection and deceptive trade practice laws.You’ll hear how the end of the FDA shortage changed what compounding pharmacies are legally allowed to do, why “research grade” GLP-1 products are not a workaround, and how recent enforcement actions in Alabama and Connecticut are reshaping diligence expectations.This episode walks through the red flags buyers must catch before signing, including opaque supply chains, misleading marketing claims, research washing, and misaligned informed consent. It also explains why missing these issues can lead to asset freezes, injunctions, multi-state investigations, and massive post-closing remediation costs.If you advise on med spa transactions, private equity healthcare deals, or GLP-1-driven growth strategies, this conversation is essential listening.For deeper diligence support on GLP-1 programs and healthcare transactions, reach out to the Kulkarni Law Firm.Subscribe for more conversations at the intersection of M&A, FDA regulation, state enforcement, and healthcare compliance.Support the showwww.kulkarnilawfirm.com

Send us Fan MailFor decades, biotech M&A followed a familiar script. Patents drove value. Molecules closed deals.That script is breaking.In today’s precision medicine transactions, the real asset is data. Longitudinal patient records, real-world evidence, and genomic datasets are now central to valuation. But unlike traditional IP, data comes with strings attached. Privacy laws, patient consent, and transfer restrictions can quietly determine whether that data is an asset or a liability.In this episode of KLF Deep Dive, we explore why clinical data is being treated as the new IP in biotech M&A, how weak consent frameworks can destroy deal value, and what acquirers should be asking during diligence before it’s too late.If you work in biotech, pharma, corporate development, or private equity, this episode breaks down a risk that is reshaping how deals get priced and structured.Listen in, and reach out if this issue is sitting inside one of your transactions.Episode HighlightsWhy patents alone no longer drive biotech valuationsHow precision medicine changed the M&A playbookClinical data as a regulated assetPatient consent and data transfer risksWhen valuable datasets become compliance liabilitiesWhat smart buyers are doing differently in diligenceSupport the showwww.kulkarnilawfirm.com

Send us Fan MailStaffing and training are not just operational issues. They are inspection risks. In this episode, we break down what sponsors and regulators actually expect when it comes to site staff training. Competent staff is not enough if training is not documented. We walk through common failure points seen during FDA inspections, including missing GCP documentation, unclear staff roles, and poor escalation processes. We also discuss how structured SOPs, training logs, and clear contracts with coordinators and sub-investigators help demonstrate a real culture of compliance. The goal is simple. When sponsors or the FDA review your site, your records should tell a clear, defensible story.Key Topics CoveredGCP training and documentation expectationsWhy undocumented training creates inspection riskCommon staffing failures seen during FDA inspectionsTraining SOPs and staff training logsDefining roles and liability in staff contractsManaging protocol deviations and escalation pathsDemonstrating a culture of compliance at the site levelWho This Is ForClinical trial sitesSponsors and CROsPrincipal InvestigatorsStudy coordinatorsClinical operations leadersSupport the showwww.kulkarnilawfirm.com

Send us Fan Mail Early termination by a sponsor can leave a clinical research site holding the bill for prep work, fees, and staffing. In this episode, Darshan explains the contract language every site should insist on to stay protected. He covers guaranteed payment for all work performed up to the termination date, reimbursement for non-cancelable expenses like IRB fees and advertising, and why a wind-down clause is essential for chart reviews, final visits, and data queries. He also explores when minimum payments or upfront funds are realistic to request. Protecting these terms upfront keeps an unexpected sponsor exit from destabilizing your operations. If you have question, Call 302.252.6959, click www.kulkarnilawfirm.com , or email [email protected]. Support the showwww.kulkarnilawfirm.com

Send us Fan MailYour skincare product may look like a cosmetic, but one wrong claim can legally turn it into an unapproved drug.In this episode of KLF Deep Dive, we break down the exact words, phrases, and influencer mistakes that push cosmetic brands straight into FDA drug territory. Anti-inflammatory claims. Acne treatment language. Collagen rebuilding promises. Detox buzzwords. These are not harmless marketing fluff. They are regulatory landmines.We explain how the FDA actually classifies products, why intent does not matter, how influencers can sink your brand, and what cosmetic companies should do right now to stay compliant.If you work in beauty, skincare, or wellness marketing, this episode can save your next launch.If compliance, enforcement, or deals matter to your business, subscribe to KLF Deep Dive.Support the showwww.kulkarnilawfirm.com

Send us Fan MailInfluencers can boost visibility fast, but they also create real regulatory exposure if they go off script. The FTC requires influencers to clearly disclose any material connection to your brand, and the wrong claim in a single post can trigger enforcement or lawsuits. In this episode, I explain how I build influencer contracts with mandatory disclosure language, claim restrictions, and takedown rights. I also describe how I design monitoring systems so brands can review influencer content before or after posting, and how I create influencer playbooks to keep everyone aligned. When done right, influencer marketing becomes a compliant and scalable growth channel. Call, click, or email if you need help. Support the showwww.kulkarnilawfirm.com

Send us Fan Mail A lot of brands start with harmless wellness promises like better mood, more energy, or improved sleep. As the business grows, though, marketing often becomes bolder, and that’s where risk creeps in. The FDA steps in when your claims imply treating or preventing a disease, which can flip your product into drug or device territory. The FTC expects every wellness claim to be truthful and supported by real evidence. In this episode, I explain how I review labels, websites, and social content, map each claim to the right regulatory bucket, and draft compliant alternatives that keep your marketing appealing without triggering expensive oversight. I also build claim checklists to help teams avoid drift in the future. Call, click, or email if you need support. Support the showwww.kulkarnilawfirm.com

Send us Fan Mail A knee implant meant to restore mobility. A surgeon secretly collecting international trips and consulting checks. A device company accused of selling a product they allegedly knew would fail. This episode breaks down the Aesculap case, the $38.5M settlement, and what it teaches us about kickbacks, forged FDA documents, and the catastrophic cost of weak compliance controls. If your team works in pharma, med-tech, or clinical research, you don’t want to miss this one. Support the showwww.kulkarnilawfirm.com

Send us Fan MailIn this episode of DarshanTalks, you dive into what U.S. Food and Drug Administration (FDA) inspectors will demand when they show up on-site. You walk through the five critical documents every life-sciences or pharma company should have ready, because without them, an inspection can become a deal-breaker fast.You stress that compliance isn’t just paperwork; it’s the backbone of long-term viability. A weak document trail, sloppy record-keeping, or missing records can lead to penalties, regulatory exposure, or even shutdowns. Tight compliance and strong documentation aren’t optional. They’re deal insurance.The episode gives concrete guidance on what to have in place before regulators knock. It’s essential listening for executives, compliance officers, and M&A advisors in biotech, pharma, and medical device businesses.Support the showwww.kulkarnilawfirm.com

Send us Fan Mail Beauty brands hit trouble when they forget they’re dealing with two regulators, not one. The FDA controls how cosmetics are labeled and when a claim crosses into drug territory. The FTC cares about whether your marketing is truthful, especially online, and expects competent and reliable scientific evidence for every objective claim you make. Say “clinically proven” without real clinical data and both agencies may come knocking. In this quick breakdown, I explain how to align your claims so they excite consumers while staying compliant. Protect your brand, limit risk, and build trust. Call, click, or email if you need help. Support the showwww.kulkarnilawfirm.com

Send us Fan MailClinical research sites lose money when sponsor contracts skip the real costs of running a study. In this episode, Darshan breaks down how to protect your site by building a detailed, task-based budget instead of accepting broad lump-sum payments. He explains why every activity needs to be itemized, from screen failures and pharmacy prep to coordinator overtime and regulatory time. You’ll hear practical tips on tying costs to CPT codes, adding overhead where possible, and making sure you can bill for out-of-scope work like unexpected SAEs and follow-up. He also highlights a commonly overlooked issue: what gets paid when the contract ends. Chart reviews, data queries, and PI closeout time all need clear language. If it’s not written down, it won’t get paid. This quick guide helps sites negotiate smarter and stay financially healthy. Call 302.252.6959 if you have questions, or email [email protected] the showwww.kulkarnilawfirm.com

Send us Fan MailBefore-and-after photos and glowing testimonials can sell products fast, but they’re also some of the most heavily scrutinized tools in advertising. The FTC requires that any endorsement reflect typical results, and the old “results not typical” fine print no longer cuts it. In this episode, I explain how I review and edit testimonials for compliant disclosures, how I evaluate before-and-after images for accuracy, permissions, and unintentional manipulation, and how I help brands build clear internal policies to prevent drift. The goal is to keep authentic customer stories in your marketing without escalating your legal risk. Call, click, or email if you need help tightening this up. Support the showwww.kulkarnilawfirm.com